跳至主要内容
临床试验/EUCTR2007-002455-16-DE
EUCTR2007-002455-16-DE进行中(未招募)不适用

Efficacy and safety of GV 550 in acute adenoviral keratoconjunctivitis

aboratoires Théa0 个研究点目标入组 80 人开始时间: 2007年7月31日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Written informed consent
  • Male or female aged from 18 to 80 years old
  • Acute adenoviral keratoconjunctivitis clinically diagnosed on the basis of:
  • First episode
  • With an history of unilateral occurrence
  • Recent (first symptoms lasting less than 3 days)
  • Conjunctival injection
  • Without infiltrates
  • Without purulent secretion
  • With positive rapid test diagnosis (RPS Adeno-detector®)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Active ocular allergy, Ocular herpes disease
  • History of bacterial conjunctivitis / blepharoconjunctivitis within the last month before the inclusion visit
  • Any relevant ocular anomaly interfering with ocular surface: chemical burns, corneal distrophy, orbital radiotherapy, progressive involvement after traumatism, etc…….
  • Best far corrected visual acuity = 1/10
  • By questioning: Any known medical or surgical history, disorder or disease such as acute or chronic severe organic disease
  • Known hypersensitivity to one of the components of the study products.
  • Pregnancy, lactation for women
  • Non compliant patient (e.g. not willing to attend the follow-up visits, way of life interfering with compliance, man who is not using a local contraceptive method such as condom).

研究者

发起方
aboratoires Théa

相似试验